As of 2025-12-24, the Intrinsic Value of Algernon Pharmaceuticals Inc (AGN.CN) is -0.26 CAD. This AGN.CN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 CAD, the upside of Algernon Pharmaceuticals Inc is -420.71%.
Based on its market price of 0.08 CAD and our intrinsic valuation, Algernon Pharmaceuticals Inc (AGN.CN) is overvalued by 420.71%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.26 - -0.26 | -0.26 | -420.71% |
| P/E | (0.00) - (0.00) | (0.00) | -103.2% |
| DDM - Stable | (1.03) - 3.97 | 1.47 | 1741.6% |
| DDM - Multi | (0.30) - 0.91 | (0.90) | -1223.6% |
| Market Cap (mil) | 2.74 |
| Beta | -0.36 |
| Outstanding shares (mil) | 34.26 |
| Enterprise Value (mil) | 2.65 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.17% |
| Cost of Debt | 5.00% |
| WACC | 4.43% |